• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
National Eye Institute - Product Pipeline Review - Q4 2010 Product Image

National Eye Institute - Product Pipeline Review - Q4 2010

  • ID: 1447153
  • December 2010
  • 87 pages
  • Global Markets Direct

National Eye Institute – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “National Eye Institute – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by National Eye Institute.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of National Eye Institute with complete description READ MORE >



List of Tables
List of Figures
National Eye Institute Snapshot
National Eye Institute Overview
Key Information
Key Facts
National Eye Institute – Research and Development Overview
Key Therapeutic Areas
National Eye Institute – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
National Eye Institute – Pipeline Products Glance
National Eye Institute – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
National Eye Institute Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
National Eye Institute – Drug Profiles
Aspirin
Product Description
Mechanism of Action
R&D Progress
Atropine for Amblyopia
Product Description
Mechanism of Action
R&D Progress
Avastin
Product Description
Mechanism of Action
R&D Progress
Cidofovir
Product Description
Mechanism of Action
R&D Progress
Cidofovir
Product Description
Mechanism of Action
R&D Progress
Enbrel
Product Description
Mechanism of Action
R&D Progress
Erythromycin
Product Description
Mechanism of Action
R&D Progress
Immunoglobulin
Product Description
Mechanism of Action
R&D Progress
Lucentis
Product Description
Mechanism of Action
R&D Progress
Lucentis + Laser Photocoagulation for DME and Diabetic Retinopathy (National Eye Institute)
Product Description
Mechanism of Action
R&D Progress
Lucentis for Diabetic Macular Edema and Diabetic Retinopathy (National Eye Institute)
Product Description
Mechanism of Action
R&D Progress
MSL-109
Product Description
Mechanism of Action
R&D Progress
Ranibizumab
Product Description
Mechanism of Action
R&D Progress
Ranibizumab + Laser Photocoagulation
Product Description
Mechanism of Action
R&D Progress
Silver Nitrate
Product Description
Mechanism of Action
R&D Progress
Triamcinolone acetonide + Laser photocoagulation
Product Description
Mechanism of Action
R&D Progress
Triamcinolone Acetonide + Laser Photocoagulation for DME and Diabetic Retinopathy (National Eye Inst
Product Description
Mechanism of Action
R&D Progress
Triamcinolone Acetonide for DME and Diabetic Retinopathy (National Eye Institute)
Product Description
Mechanism of Action
R&D Progress
Avastin
Product Description
Mechanism of Action
R&D Progress
Cyclosporin A
Product Description
Mechanism of Action
R&D Progress
Cysteamine
Product Description
Mechanism of Action
R&D Progress
Daclizumab
Product Description
Mechanism of Action
R&D Progress
Daclizumab
Product Description
Mechanism of Action
R&D Progress
Daclizumab + Denileukin Diftitox
Product Description
Mechanism of Action
R&D Progress
Finasteride
Product Description
Mechanism of Action
R&D Progress
Leflunomide
Product Description
Mechanism of Action
R&D Progress
Microplasmin
Product Description
Mechanism of Action
R&D Progress
Minocycline
Product Description
Mechanism of Action
R&D Progress
Optiquel
Product Description
Mechanism of Action
R&D Progress
OT-551
Product Description
Mechanism of Action
R&D Progress
Sirolimus
Product Description
Mechanism of Action
R&D Progress
Sunitinib Malate
Product Description
Mechanism of Action
R&D Progress
Sutent
Product Description
Mechanism of Action
R&D Progress
Zenapax
Product Description
Mechanism of Action
R&D Progress
Centrum
Product Description
Mechanism of Action
R&D Progress
Colloral
Product Description
Mechanism of Action
R&D Progress
Corticosteroid
Product Description
Mechanism of Action
R&D Progress
Cyclosporin A
Product Description
Mechanism of Action
R&D Progress
EYE001
Product Description
Mechanism of Action
R&D Progress
Fluocinolone
Product Description
Mechanism of Action
R&D Progress
Interferon Gamma 1-b
Product Description
Mechanism of Action
R&D Progress
Raptiva
Product Description
Mechanism of Action
R&D Progress
Remicade
Product Description
Mechanism of Action
R&D Progress
Rituximab
Product Description
Mechanism of Action
R&D Progress
Sirolimus
Product Description
Mechanism of Action
R&D Progress
Subconjunctival Cyclosporine Implant
Product Description
Mechanism of Action
R&D Progress
Zenapax
Product Description
Mechanism of Action
R&D Progress
National Eye Institute – Pipeline Analysis
National Eye Institute – Pipeline Products by Therapeutic Class
National Eye Institute Pipeline Products By Target
National Eye Institute – Pipeline Products by Route of Administration
National Eye Institute – Pipeline Products by Molecule Type
National Eye Institute – Recent Pipeline Updates
National Eye Institute - Dormant Projects
National Eye Institute – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS